Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Guanine nucleotide-binding protein-like 1 (GNL1)
- Target
- GNL1
- Molecular classification
- Other (nucleolar GTPase, not a classical receptor, enzyme, or transporter)
01
Overview
Guanine nucleotide-binding protein-like 1 (GNL1) is an evolutionarily conserved putative nucleolar GTPase of the HSR1_MMR1 GTPase subfamily, predominantly localized in the nucleolus with nuclear-cytoplasmic shuttling that's dependent on the cell cycle. GNL1 is upregulated in several human cancers and promotes cell proliferation and survival, at least in part, by activating the AKT/p21 signaling pathway, stabilizing cytoplasmic p21, inhibiting apoptosis via modulation of Bcl2 family proteins and caspases, and enhancing cell cycle progression through effects on pRb phosphorylation and G1/S and G2/M phase transitions. Increased GNL1 correlates with poor clinical outcome in some cancer types and suggests involvement in tumorigenesis. There are currently no reported drugs or inhibitors specifically targeting GNL1 in clinical use or development.
- Other names
- G protein nucleolar 1HSR1GTP-binding protein HSR1guanine nucleotide-binding protein-like 1
02
Biological functions
Cell cycle regulationCell proliferationApoptosis inhibitionSignal transduction (via AKT/p21 signaling pathway)
03
Disease associations
Cancer (promotes tumorigenesis and cell survival)possibly developmental disorders such as "Multiple Benign Circumferential Skin Creases On Limbs" and "Goldberg-Shprintzen Syndrome"
04
Biomarkers
High GNL1 expression correlates with poor survival in certain cancers, suggesting use as a prognostic biomarker
Beyond the preview
Go deeper on Guanine nucleotide-binding protein-like 1 (GNL1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guanine nucleotide-binding protein-like 1 (GNL1).